Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 164

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer

Open access
Lemieux, E, Cagnol, S, Beaudry, K, Carrier, J, Rivard, N·2015·Oncogene

Abstract

Aberrant regulation of the Wnt/β-catenin signaling pathway is one of the major causes of colorectal cancer (CRC). Loss-of-function mutations in APC are commonly found in CRC, leading to inappropriate activation of canonical Wnt signaling. Conversely, gain-of-function mutations in KRAS and BRAF genes are detected in up to 60% of CRCs. Whereas KRAS/mitogen-activated protein kinase (MAPK) and canonical Wnt/β-catenin pathways are critical for intestinal tumorigenesis, mechanisms integrating these two important signaling pathways during CRC development are unknown. Results herein demonstrate that transformation of normal intestinal epithelial cells (IECs) by oncogenic forms of KRAS, BRAF or MEK1 was associated with a marked increase in β-catenin/TCF4 and c-MYC promoter transcriptional activities and mRNA levels of c-Myc, Axin2 and Lef1. Notably, expression of a dominant-negative mutant of T-Cell Factor 4 (ΔNTCF4) severely attenuated IEC transformation induced by oncogenic MEK1 and markedly reduced their tumorigenic and metastatic potential in immunocompromised mice. Interestingly, the Frizzled co-receptor LRP6 was phosphorylated in a MEK-dependent manner in transformed IECs and in human CRC cell lines. Expression of LRP6 mutant in which serine/threonine residues in each particular ProlineProlineProlineSerine/ThreonineProline motif were mutated to alanines (LRP6-5A) significantly reduced β-catenin/TCF4 transcriptional activity. Accordingly, MEK inhibition in human CRC cells significantly diminished β-catenin/TCF4 transcriptional activity and c-MYC mRNA and protein levels without affecting β-catenin expression or stability. Lastly, LRP6 phosphorylation was also increased in human colorectal tumors, including adenomas, in comparison with healthy adjacent normal tissues. Our data indicate that oncogenic activation of KRAS/BRAF/MEK signaling stimulates the canonical Wnt/β-catenin pathway, which in turn promotes intestinal tumor growth and invasion. Moreover, LRP6 phosphorylation by ERK1/2 may provide a unique point of convergence between KRAS/MAPK and Wnt/β-catenin signalings during oncogenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/onc.2014.416

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 78

  1. Fearon ER, Vogelstein B . A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–767. · DOI · Paper page
  2. Gregorieff A, Clevers H . Wnt signalling in the intestinal epithelium: from endoderm to cancer. Genes Dev 2005; 19: 877–890. · DOI · Paper page
  3. Taketo MM . Mouse models of gastrointestinal tumors. Cancer Sci 2006; 97: 355–361. · DOI
  4. Ashton GH, Morton JP, Myant K, Phesse TJ, Ridgway RA, Marsh V et al. Focal adhesion kinase is required for intestinal regeneration and tumorigenesis downstream of Wnt/c-Myc signalling. Dev Cell 2010; 19: 259–269. · DOI · Paper page
  5. Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, Reed KR et al. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007; 446: 676–679. · DOI · Paper page
  6. Worthley DL, Leggett BA . Colorectal cancer: molecular features and clinical opportunities. Clin Biochem Rev 2010; 31: 31–38.
  7. Pretlow TP, Pretlow TG . Mutant KRAS in aberrant crypt foci (ACF): initiation of colorectal cancer? Biochim Biophys Acta 2005; 1756: 83–96.
  8. Smakman N, Borel Rinkes IH, Voest EE, Kranenburg O . Control of colorectal metastasis formation by K-Ras. Biochim Biophys Acta 2005; 1756: 103–114.
  9. Saucier C, Rivard N . Epithelial cell signalling in colorectal cancer metastasis. In: Beauchemin N, Huot J (eds) Metastasis of Colorectal Cancer vol.14. Springer: Netherlands, 2010, pp 205–241. · DOI
  10. Dasari A, Messersmith WA . New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. Clin Cancer Res 2010; 16: 3811–3818. · DOI
  11. Dienstmann R, Tabernero J . BRAF as a target for cancer therapy. Anticancer Agents Med Chem 2011; 11: 285–295. · DOI
  12. Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005; 65: 4562–4567. · DOI · Paper page
  13. Deng G, Bell I, Crawley S, Gum J, Terdiman JP, Allen BA et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004; 10: 191–195. · DOI · Paper page
  14. Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Iacopetta B . BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 2006; 5: 2. · DOI · Paper page
  15. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002; 62: 6451–6455.
  16. Ramos JW . The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol 2008; 40: 2707–2719. · DOI · Paper page
  17. Aliaga JC, Deschenes C, Beaulieu JF, Calvo EL, Rivard N . Requirement of the MAP kinase cascade for cell cycle progression and differentiation of human intestinal cells. Am J Physiol 1999; 277: G631–G641.
  18. Rivard N, Boucher MJ, Asselin C, L'Allemain G . MAP kinase cascade is required for p27 downregulation and S phase entry in fibroblasts and epithelial cells. Am J Physiol 1999; 277: C652–C664. · DOI
  19. Eggstein S, Franke M, Kutschka I, Manthey G, von Specht BU, Ruf G et al. Expression and activity of mitogen activated protein kinases in human colorectal carcinoma. Gut 1999; 44: 834–838. · DOI
  20. Lee SH, Lee JW, Soung YH, Kim SY, Nam SW, Park WS et al. Colorectal tumors frequently express phosphorylated mitogen-activated protein kinase. APMIS 2004; 112: 233–238. · DOI
  21. Boucher MJ, Jean D, Vezina A, Rivard N . Dual role of MEK/ERK signalling in senescence and transformation of intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2004; 286: G736–G746. · DOI
  22. Lemieux E, Bergeron S, Durand V, Asselin C, Saucier C, Rivard N . Constitutively active MEK1 is sufficient to induce epithelial-to-mesenchymal transition in intestinal epithelial cells and to promote tumor invasion and metastasis. Int J Cancer 2009; 125: 1575–1586. · DOI
  23. Komatsu K, Buchanan FG, Katkuri S, Morrow JD, Inoue H, Otaka M et al. Oncogenic potential of MEK1 in rat intestinal epithelial cells is mediated via cyclooxygenase-2. Gastroenterology 2005; 129: 577–590. · DOI
  24. Voisin L, Julien C, Duhamel S, Gopalbhai K, Claveau I, Saba-El-Leil MK et al. Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors. BMC Cancer 2008; 8: 337–2407-8-337. · DOI
  25. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999; 5: 810–816. · DOI · Paper page
  26. Ikenoue T, Hikiba Y, Kanai F, Aragaki J, Tanaka Y, Imamura J et al. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation. Cancer Res 2004; 64: 3428–3435. · DOI
  27. Cagnol S, Rivard N . Oncogenic KRAS and BRAF activation of the MEK/ERK signalling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition. Oncogene 2013; 32: 564–576. · DOI
  28. Nandan MO, McConnell BB, Ghaleb AM, Bialkowska AB, Sheng H, Shao J et al. Kruppel-like factor 5 mediates cellular transformation during oncogenic KRAS-induced intestinal tumorigenesis. Gastroenterology 2008; 134: 120–130. · DOI
  29. Brondello JM, Brunet A, Pouyssegur J, McKenzie FR . The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade. J Biol Chem 1997; 272: 1368–1376. · DOI · Paper page
  30. Brunet A, Pages G, Pouyssegur J . Growth factor-stimulated MAP kinase induces rapid retro-phosphorylation and inhibition of MAP kinase kinase (MEK1). FEBS Lett 1994; 346: 299–303. · DOI
  31. Gopalbhai K, Meloche S . Repression of mitogen-activated protein kinases ERK1/ERK2 activity by a protein tyrosine phosphatase in rat fibroblasts transformed by upstream oncoproteins. J Cell Physiol 1998; 174: 35–47. · doi:10.1002/(sici)1097-4652(199801)174:1<35::aid-jcp5>3.0.co;2-h
  32. Tian X, Liu Z, Niu B, Zhang J, Tan TK, Lee SR et al. E-cadherin/beta-catenin complex and the epithelial barrier. J Biomed Biotechnol 2011; 2011: 567305.
  33. Yochum GS, Cleland R, Goodman RH . A genome-wide screen for beta-catenin binding sites identifies a downstream enhancer element that controls c-Myc gene expression. Mol Cell Biol 2008; 28: 7368–7379. · DOI
  34. Clevers H . Wnt/beta-catenin signalling in development and disease. Cell 2006; 127: 469–480. · DOI · Paper page
  35. Naishiro Y, Yamada T, Takaoka AS, Hayashi R, Hasegawa F, Imai K et al. Restoration of epithelial cell polarity in a colorectal cancer cell line by suppression of beta-catenin/T-cell factor 4-mediated gene transactivation. Cancer Res 2001; 61: 2751–2758.
  36. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111: 241–250. · DOI · Paper page
  37. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription. Proc Natl Acad Sci USA 2004; 101: 12682–12687. · DOI · Paper page
  38. Rowan AJ, Lamlum H, Ilyas M, Wheeler J, Straub J, Papadopoulou A et al. APC mutations in sporadic colorectal tumors: A mutational "hotspot" and interdependence of the "two hits". Proc Natl Acad Sci USA 2000; 97: 3352–3357. · DOI · Paper page
  39. Yang J, Zhang W, Evans PM, Chen X, He X, Liu C . Adenomatous polyposis coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon cancer cells. J Biol Chem 2006; 281: 17751–17757. · DOI · Paper page
  40. Hart M, Concordet JP, Lassot I, Albert I, del los Santos R, Durand H et al. The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 1999; 9: 207–210. · DOI · Paper page
  41. Piedra J, Miravet S, Castano J, Palmer HG, Heisterkamp N, Garcia de Herreros A et al. p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin Interaction. Mol Cell Biol 2003; 23: 2287–2297. · DOI · Paper page
  42. Brembeck FH, Schwarz-Romond T, Bakkers J, Wilhelm S, Hammerschmidt M, Birchmeier W . Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions. Genes Dev 2004; 18: 2225–2230. · DOI · Paper page
  43. Roura S, Miravet S, Piedra J, Garcia de Herreros A, Dunach M . Regulation of E-cadherin/Catenin association by tyrosine phosphorylation. J Biol Chem 1999; 274: 36734–36740. · DOI · Paper page
  44. Taurin S, Sandbo N, Qin Y, Browning D, Dulin NO . Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem 2006; 281: 9971–9976. · DOI · Paper page
  45. Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H et al. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem 2007; 282: 11221–11229. · DOI · Paper page
  46. He XC, Yin T, Grindley JC, Tian Q, Sato T, Tao WA et al. PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet 2007; 39: 189–198. · DOI · Paper page
  47. Krejci P, Aklian A, Kaucka M, Sevcikova E, Prochazkova J, Masek JK et al. Receptor tyrosine kinases activate canonical WNT/beta-catenin signalling via MAP kinase/LRP6 pathway and direct beta-catenin phosphorylation. PLoS ONE 2012; 7: e35826. · DOI · Paper page
  48. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE J et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009; 41: 544–552. · DOI · Paper page
  49. Casalino L, De Cesare D, Verde P . Accumulation of Fra-1 in ras-transformed cells depends on both transcriptional autoregulation and MEK-dependent posttranslational stabilization. Mol Cell Biol 2003; 23: 4401–4415. · DOI
  50. Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci USA 2013; 110: 20224–20229. · DOI · Paper page
  51. Proffitt KD, Virshup DM . Precise regulation of porcupine activity is required for physiological Wnt signalling. J Biol Chem 2012; 287: 34167–34178. · DOI
  52. Fernandez-Medarde A, Santos E . Ras in cancer and developmental diseases. Genes Cancer 2011; 2: 344–358. · DOI · Paper page
  53. Niault TS, Baccarini M . Targets of Raf in tumorigenesis. Carcinogenesis 2010; 31: 1165–1174. · DOI
  54. Daugherty RL, Gottardi CJ . Phospho-regulation of Beta-catenin adhesion and signalling functions. Physiology (Bethesda) 2007; 22: 303–309.
  55. Bienz M . beta-Catenin: a pivot between cell adhesion and Wnt signalling. Curr Biol 2005; 15: R64–R67. · DOI · Paper page
  56. Gumbiner BM . Regulation of cadherin adhesive activity. J Cell Biol 2000; 148: 399–404. · DOI · Paper page
  57. Harris TJ, Peifer M . Decisions, decisions: beta-catenin chooses between adhesion and transcription. Trends Cell Biol 2005; 15: 234–237. · DOI · Paper page
  58. Nelson WJ, Nusse R . Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004; 303: 1483–1487. · DOI · Paper page
  59. Perez-Moreno M, Fuchs E . Catenins: keeping cells from getting their signals crossed. Dev Cell 2006; 11: 601–612. · DOI · Paper page
  60. Singh A, Sweeney MF, Yu M, Burger A, Greninger P, Benes C et al. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 2012; 148: 639–650. · DOI · Paper page
  61. Horst D, Chen J, Morikawa T, Ogino S, Kirchner T, Shivdasani RA . Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signalling. Cancer Res 2012; 72: 1547–1556. · DOI
  62. Wang C, Zhao R, Huang P, Yang F, Quan Z, Xu N et al. APC loss-induced intestinal tumorigenesis in Drosophila: roles of Ras in Wnt signalling activation and tumor progression. Dev Biol 2013; 378: 122–140. · DOI
  63. Rad R, Cadinanos J, Rad L, Varela I, Strong A, Kriegl L et al. A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell 2013; 24: 15–29. · DOI · Paper page
  64. Zeller E, Hammer K, Kirschnick M, Braeuning A . Mechanisms of RAS/beta-catenin interactions. Arch Toxicol 2013; 87: 611–632. · DOI
  65. Fodde R, Tomlinson I . Nuclear beta-catenin expression and Wnt signalling: in defence of the dogma. J Pathol 2010; 221: 239–241. · DOI
  66. Tamai K, Zeng X, Liu C, Zhang X, Harada Y, Chang Z et al. A mechanism for Wnt coreceptor activation. Mol Cell 2004; 13: 149–156. · DOI · Paper page
  67. Wolf J, Palmby TR, Gavard J, Williams BO, Gutkind JS . Multiple PPPS/TP motifs act in a combinatorial fashion to transduce Wnt signalling through LRP6. FEBS Lett 2008; 582: 255–261. · DOI
  68. Wu X, Tu X, Joeng KS, Hilton MJ, Williams DA, Long F . Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signalling. Cell 2008; 133: 340–353. · DOI · Paper page
  69. Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P et al. APC and oncogenic KRAS are synergistic in enhancing Wnt signalling in intestinal tumor formation and progression. Gastroenterology 2006; 131: 1096–1109. · DOI · Paper page
  70. Luo F, Brooks DG, Ye H, Hamoudi R, Poulogiannis G, Patek CE et al. Mutated K-ras(Asp12) promotes tumourigenesis in Apc(Min) mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways. Int J Exp Pathol 2009; 90: 558–574. · DOI
  71. Lee SH, Hu LL, Gonzalez-Navajas J, Seo GS, Shen C, Brick J et al. ERK activation drives intestinal tumorigenesis in Apc(min/+) mice. Nat Med 2010; 16: 665–670. · DOI · Paper page
  72. Obrador-Hevia A, Chin SF, Gonzalez S, Rees J, Vilardell F, Greenson JK et al. Oncogenic KRAS is not necessary for Wnt signalling activation in APC-associated FAP adenomas. J Pathol 2010; 221: 57–67. · DOI
  73. Kahn M . Can we safely target the WNT pathway? Nat Rev Drug Discov 2014; 13: 513–532. · DOI · Paper page
  74. Ettenberg SA, Charlat O, Daley MP, Liu S, Vincent KJ, Stuart DD et al. Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proc Natl Acad Sci USA 2010; 107: 15473–15478. · DOI
  75. Bergeron S, Lemieux E, Durand V, Cagnol S, Carrier JC, Lussier JG et al. The serine protease inhibitor serpinE2 is a novel target of ERK signalling involved in human colorectal tumorigenesis. Mol Cancer 2010; 9: 271–4598-9-271. · DOI
  76. Simoneau M, Coulombe G, Vandal G, Vezina A, Rivard N . SHP-1 inhibits beta-catenin function by inducing its degradation and interfering with its association with TATA-binding protein. Cell Signal 2011; 23: 269–279. · DOI
  77. Langlois MJ, Bergeron S, Bernatchez G, Boudreau F, Saucier C, Perreault N et al. The PTEN phosphatase controls intestinal epithelial cell polarity and barrier function: role in colorectal cancer progression. PLoS ONE 2010; 5: e15742. · DOI
  78. Madison BB, Dunbar L, Qiao XT, Braunstein K, Braunstein E, Gumucio DL . Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J Biol Chem 2002; 277: 33275–33283. · DOI · Paper page

Cited by

See all 164

Metadata

Authors
Lemieux, E., Cagnol, S., Beaudry, K., Carrier, J., & Rivard, N.
Venue
Oncogene
Published
2014-12-15
Volume
34
Issue
38
Pages
4914-4927
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W2070746836
Cited by
164
References
8
FWCI
6.33
Type
journal article
Language
en
Open access
hybrid
Licence
creativecommons.org/licenses/by-nc-nd/4.0 (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer. https://app.cochat.ai/papers/10.1038/onc.2014.416
The paper
Lemieux, E., Cagnol, S., Beaudry, K., Carrier, J., & Rivard, N. (2015). Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer. Oncogene. https://doi.org/10.1038/onc.2014.416

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.